Characterizing septum inhibition in Mycobacterium tuberculosis for novel drug discovery

被引:26
|
作者
Respicio, Laurel [2 ]
Nair, Pravin A. [1 ]
Huang, Qing [1 ]
Anil, Burcu [1 ]
Tracz, Sylvia [1 ]
Truglio, James J. [3 ]
Kisker, Caroline [4 ]
Raleigh, Daniel P. [1 ]
Ojima, Iwao [1 ]
Knudson, Dennis L. [5 ]
Tonge, Peter J. [1 ]
Slayden, Richard A. [2 ]
机构
[1] SUNY Stony Brook, Dept Chem, Inst Chem Biol & Drug Discovery, Stony Brook, NY 11794 USA
[2] Colorado State Univ, Dept Microbiol & Immunol Pathol, Mycobacteria Res Labs, Rocky Mt Reg Ctr Excellence, Ft Collins, CO 80523 USA
[3] SUNY Stony Brook, Struct Biol Ctr, Stony Brook, NY 11794 USA
[4] Univ Wurzburg, Inst Biol Struct, Rudolf Virchow Ctr Expt Biomed, D-97078 Wurzburg, Germany
[5] Colorado State Univ, Dept Bioagr Sci & Pest Management, Ft Collins, CO 80523 USA
关键词
Mycobacterium tuberculosis; cell division; FtsZ; septum inhibition; drug discovery;
D O I
10.1016/j.tube.2008.03.001
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A temperature sensitive mutation in the cell, division protein FtsZ was used in combination with transcriptional analysis to identify biomarkers for inhibition of septum formation. Crystallography and modeling revealed that the glycine for aspartate substitution at amino acid 210 was located in helix 8 of the protein, adjacent to the T7 synergy loop. To verify the molecular behavior of FtSZ(D210G), the in vitro activity and structural stability were evaluated as a function of temperature. These analyses confirmed that the FtsZ(D21OG) mutant had reduced GTPase and polymerization activity compared to wild-type FtsZ, and CD spectroscopy demonstrated that both FtsZD21OG and wild-type FtsZ had similar structure and stability. Significantly, the FtsZD21OG merodiploid strain of A tuberculosis had compromised growth at 37 degrees C, substantiating the suitability of FtSZ(D21OG) as a molecular toot for global analysis in response to improper FtsZ polymerization and septum inhibition. Advanced model-based bioinformatics and transcriptional mapping were used to identify high-content multiple features that provide biomarkers for the development of a rational drug screening platform for discovering novel chemotherapeutics that target cell division. (c) 2008 Published by Elsevier Ltd.
引用
收藏
页码:420 / 429
页数:10
相关论文
共 50 条
  • [41] The impact of machine learning on future tuberculosis drug discovery
    Winkler, David A.
    EXPERT OPINION ON DRUG DISCOVERY, 2022, 17 (09) : 925 - 927
  • [42] Drug targets exploited in Mycobacterium tuberculosis: Pitfalls and promises on the horizon
    Bhat, Zubair Shanib
    Rather, Muzafar Ahmad
    Maqbool, Mubashir
    Ahmad, Zahoor
    BIOMEDICINE & PHARMACOTHERAPY, 2018, 103 : 1733 - 1747
  • [43] Amino Acid Biosynthesis Inhibitors in Tuberculosis Drug Discovery
    Guida, Michela
    Tammaro, Chiara
    Quaranta, Miriana
    Salvucci, Benedetta
    Biava, Mariangela
    Poce, Giovanna
    Consalvi, Sara
    PHARMACEUTICS, 2024, 16 (06)
  • [44] EFFECT OF SOME MEDICINAL PLANTS ON GROWTH OF MYCOBACTERIUM TUBERCULOSIS, MULTI DRUG RESISTANT MYCOBACTERIUM TUBERCULOSIS AND MYCOBACTERIUM OTHER THAN TUBERCULOSIS
    Shukla, Prashant
    Sharma, Ajay
    JOURNAL OF MICROBIOLOGY BIOTECHNOLOGY AND FOOD SCIENCES, 2013, 3 (03): : 199 - 201
  • [45] Structure based virtual screening and discovery of novel inhibitors against FabD protein of Mycobacterium tuberculosis
    Sundararajan, Sadhana
    Karunakaran, Keerthana
    Muniyan, Rajiniraja
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2024, 42 (12) : 6280 - 6291
  • [46] Fragment Discovery for the Design of Nitrogen Heterocycles as Mycobacterium tuberculosis Dihydrofolate Reductase Inhibitors
    Shelke, Rupesh U.
    Degani, Mariam S.
    Raju, Archana
    Ray, Mukti Kanta
    Rajan, Mysore G. R.
    ARCHIV DER PHARMAZIE, 2016, 349 (08) : 602 - 613
  • [47] Bottlenecks and opportunities in antibiotic discovery against Mycobacterium tuberculosis
    Craggs, Peter D.
    de Carvalho, Luiz Pedro S.
    CURRENT OPINION IN MICROBIOLOGY, 2022, 69
  • [48] Exploring the structure of glutamate racemase from Mycobacterium tuberculosis as a template for anti-mycobacterial drug discovery
    Poen, Sinothai
    Nakatani, Yoshio
    Opel-Reading, Helen K.
    Lasse, Moritz
    Dobson, Renwick C. J.
    Krause, Kurt L.
    BIOCHEMICAL JOURNAL, 2016, 473 : 1267 - 1280
  • [49] Inducing vulnerability to InhA inhibition restores isoniazid susceptibility in drug-resistant Mycobacterium tuberculosis
    Harrison, Gregory A.
    Wang, Erin R.
    Cho, Kevin
    Mreyoud, Yassin
    Sarkar, Souvik
    Almqvist, Fredrik
    Patti, Gary J.
    Stallings, Christina L.
    MBIO, 2024, 15 (03):
  • [50] Editorial: Tuberculosis Drug Discovery & Development: Drug Targets, Chemical Matter, and Approaches
    Singh, Vinayak
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2021, 11